Epcoritamab-bysp (Epkinly) — CPB 1034 | AETNA Coverage Update

Aetna modified CPB 1034 for epcoritamab-bysp (Epkinly), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its epcoritamab-bysp (Epkinly) coverage policy under CPB 1034 Aetna system, with the effective date of September 26, 2025. This update expands and clarifies medical necessity criteria for B-cell lymphoma treatment across two distinct clinical pathways. If your team bills J9321 (epcoritamab-bysp injection) or administers it under CPT 96401, this policy change affects your prior authorization workflow and your ICD-10 code selection directly.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Epcoritamab-bysp (Epkinly) — CPB 1034
Policy Code	CPB 1034
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Hematology/Oncology, Infusion, Specialty Pharmacy
Key Action	Confirm your ICD-10 code maps to an approved subtype and that prior authorization is in place before billing J9321

---

Aetna Epcoritamab-bysp Coverage Criteria and Medical Necessity Requirements 2025

The Aetna epcoritamab-bysp coverage policy under CPB 1034 splits approval into two clinical pathways. Each pathway has specific subtype requirements. Get the wrong one, and you'll get a claim denial.

Pathway 1: Combination therapy with GemOx (gemcitabine and oxaliplatin)

Aetna considers epcoritamab-bysp medically necessary as subsequent therapy in combination with GemOx for relapsed or refractory disease. The member's diagnosis must fall into one of these subtypes:

Pathway 2: Single-agent therapy after ≥2 prior lines of systemic therapy

For single-agent use, the member must show partial response, no response, progressive disease, relapsed disease, or refractory disease. They must have received at least two prior lines of systemic therapy. Covered subtypes are broader here:

Follicular lymphoma only qualifies under single-agent therapy. It is not covered under the GemOx combination pathway. That distinction will cause denials if your team misreads it.

Prior authorization is required. Aetna requires precertification for all participating providers and members in applicable plan designs before epcoritamab-bysp billing can proceed. Call (866) 752-7021 or fax (888) 267-3277. You can also submit a Statement of Medical Necessity (SMN) form through Aetna's Specialty Pharmacy Precertification portal.

Don't wait until treatment starts to initiate prior authorization. The precertification requirement applies at the point of ordering. A lapse here is the most common source of avoidable claim denial on specialty oncology drugs.

Continuation of therapy / reauthorization requires showing no unacceptable toxicity and no disease progression on the current regimen. Document this clearly in the medical record before submitting reauthorization. Aetna will not continue reimbursement if progression is documented.

---

Aetna Epcoritamab-bysp Exclusions and Non-Covered Indications

Aetna's position is direct: all indications not listed in the CPB 1034 coverage policy are considered experimental, investigational, or unproven.

That language matters for billing. If a provider attempts to use epcoritamab-bysp for a B-cell lymphoma subtype not listed above — or for any non-B-cell malignancy — Aetna will deny on medical necessity grounds. There's no gray zone here. The policy doesn't say "limited coverage" for other subtypes. It says experimental and unproven.

Appeals based on off-label use will be an uphill fight. If your oncology team is considering epcoritamab-bysp for an unlisted indication, loop in your compliance officer and your billing consultant before the drug is ordered. Retroactive denials on specialty injectables at this price point are painful.

---

Coverage Indications at a Glance

One item worth flagging on that table: HIV-related plasmablastic lymphoma appears under the GemOx combination pathway but is not listed under the single-agent pathway. That's not a typo. The policy text specifically includes it under Pathway 1 and omits it under Pathway 2. If you have a plasmablastic lymphoma patient on single-agent therapy, you don't have coverage under this policy as written. Clarify with Aetna before billing.

---

Aetna Epcoritamab-bysp Billing Guidelines and Action Items 2025

These are the steps your billing team needs to take now. The effective date is September 26, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Epcoritamab-bysp Under CPB 1034

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9321	HCPCS	Injection, epcoritamab-bysp, 0.16 mg

Key ICD-10-CM Diagnosis Codes

The full CPB 1034 policy includes 154 ICD-10-CM codes. The table below includes the codes provided in the policy data. Use the most specific code that matches the confirmed diagnosis.

Note: The full CPB 1034 policy references 154 ICD-10-CM codes. The remaining 74 codes cover additional B-cell lymphoma subtypes including DLBCL, high grade B-cell lymphoma, HIV-related B-cell lymphomas, and monomorphic PTLD categories. Pull the complete code list from the CPB 1034 policy source to confirm all applicable codes for your patient population.

---